I can not emphasize this enough! If you want to be successful in this very challenging industry you must have a plan. You have to know your risk reward before you enter a trade. Often times people plan their exit around where they are going to cash out once the trade goes their way. They focus on how much money they are going to make! That is understandable since thinking about making money is more fun than thinking about losing money.
However, the most important piece that you need to define is your RISK!
How much are you willing to lose if the trade goes against you? What is the amount you are willing to give up and is it justified by the amount you plan to make if the trade works out perfectly and hits your target profit? You should have a complete detailed plan for each and every trade you take. I know that sounds unrealistic if you are a scalper but if you don't take the time to identify support and resistance, entries and exits then you are just flying blind. You have to know your risk reward so that you can identify whether it is worth getting involved.
Lending Club Sees Q4 Rev. $128-$130M vs. Est. $123.06M, FY15 Rev. $420-$422M vs. Est. $408.53M
| ||
04:22:04pm
10/29/15 |
Lending Club Reports Q3 EPS $0.04 vs. Est. $0.02, Rev. $115.1M vs. Est. $107.95M
|
Dorian LPG Reports Q2 EPS $0.72 Vs Est $0.66, Sales $74.9M Vs Est $60.46M
| ||
04:54:32pm
10/05/15 |
LPG Chairman Hadjipateras Buys 20,000 Shares @$10.72/Share -Form 4
|
Violin Memory (VMEM) announced that a major online retailer of consumer electronics has deployed the Violin 7300 Flash Storage Platform to improve its online transaction processing, critical to maintaining rapid, reliable and secure responsiveness to its customers worldwide.
RECENT insider buys @ 1.48 Can be a pop and flopper but looks like it could break that downtrend line and go for a two test
IRADIMED Raises FY15 Sales Outlook from $30.2M-$30.4M to $31.3M-$31.4M vs $30.2M Est., Adj. EPS from $0.63-$0.65 to $0.68-$0.69 vs $0.63 Est.
| ||
07:33:43am
10/30/15 |
IRADIMED Sees Q4 Sales $8.5M-$8.6M vs $7.9M Est., Adj. EPS $0.19-$0.20 vs $0.17 Est.
| |
07:33:00am
10/30/15 |
IRADIMED Reports Q3 Adj. EPS $0.19 vs $0.16 Est., Sales $8.2M vs $7.7M Est.
|
FDA Accepts for Filing Lipocine's New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
|
AcelRx Reports Q3 EPS $0.11 vs. Est. $(0.23), Rev. $15.428M vs. Est. $1.75M; Estimates Not Comp.
|
5
|
MobileIron Reports Q3 Adj. Loss of $0.17/Share vs Loss of $0.20/Share Est., Sales $38M vs $37.6M Est.; Sees Q4 Sales $41M-$42M vs $40.9M Est
|
A10 Networks Reports Q3 Adj Loss $0.07 Vs Est Loss $0.09, Sales $50.8M Vs Est $50.49M
|


No comments:
Post a Comment